Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN ISIN · CA74346M1095 LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2025-08-14 Director's Dealing
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2025-08-14 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-08-14 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-08-14 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by ProMIS Neurosciences Inc. It registers shares under stock option plans and includes detailed information about the plans, incorporation by reference of other filings (10-K, 10-Q, 8-K), and legal and procedural undertakings. Form S-8 is a registration statement for securities under employee benefit plans, not a financial report or earnings release. It is a regulatory filing related to securities registration under the Securities Act of 1933. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for SEC filings that do not fit other specific report types.
2025-08-13 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the offering and sale of securities by Promis Neurosciences Inc. The text includes a prospectus and base prospectus information, describing the terms of securities offerings, use of proceeds, risk factors, and other related disclosures. This type of filing is a capital markets document related to fundraising and securities issuance, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full filing, not just an announcement or notice.
2025-08-13 English
10-Q
Interim / Quarterly Report Q2 2025
2025-08-13 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.